Tuberculosis caused 1.3 million deaths in 2022. Drug-resistant TB cases have risen by 3% globally, with young adults ...
A new study by UCLA Health has discovered what researchers say is the first drug to fully reproduce the effects of physical ...
The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
Potent Antiviral Activity in Preclinical Challenge Model: Results from a rodent challenge model showed that 100% of mice ...
Tuberculosis, an ongoing pandemic, highlights and exacerbates global disparities. With the prevailing model of standardised treatment in vertical health programmes, it is unsurprising that ...
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date ...
A delay in drug approvals in the US market remains a concern for Aurobindo. The company stated that eight ANDAs (abbreviated ...
The nonsteroidal anti-inflammatory drug (NSAID) flunixin meglumine has been approved by the FDA for fever associated with ...
Mycobacterium abscessus is a fast-growing, pathogenic mycobacteria that can cause lung infections, and people who have ...
Shore Capital, which covers hVIVO, sees plenty of upside. The broker notes that the company’s cash generation, revenue visibility, and profitability make it an outlier in healthcare, where many firms ...